<DOC>
	<DOCNO>NCT00511823</DOCNO>
	<brief_summary>This A Three-Part Drug-Drug Interaction Study To Evaluate Effects Casopitant On Dolasetron , Granisetron Rosiglitazone When Co-Administered Healthy Adults</brief_summary>
	<brief_title>The Pharmacokinetic Interaction Between Oral Casopitant Oral Dolasetron , Granisetron Rosiglitazone Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Dolasetron</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>An adult healthy male female . Age : 18 64 year , inclusive . Body mass index ( BMI ) = 19 = 37 kg/m2 . A female Nonchildbearing potential , OR A female negative serum pregnancy test within 14 day prior first dose study medication agree use adequate contraception study 14 day last dose study medication . Adequate organ system function [ Hemoglobin within normal limit Â± 10 % ; Platelets = 100 X 109/L = low limit normal ( LLN ) ; Aspartate aminotransaminase = Upper limit normal ( ULN ) ; Total bilirubin = 1.2 time ULN ; Creatine phosphokinase &lt; 1.5 time ULN ; Renal Calculated creatinine clearance = 50 mL/min ] Able swallow retain oral medication . Able understand comply requirement , instruction restriction state informed consent . Signed date informed consent . Clinically relevant abnormality , include degree heart failure clinically significant cardiac disease , identify screen exam medical condition circumstance make subject unsuitable participation study . For Part A ( dolasetroncasopitant drugdrug interaction ) , subject exhibit gene duplication CYP2D6 . History drug allergy , opinion Investigator , contraindicate participation . Known immediate hypersensitivity reaction idiosyncrasy study drug drug chemically relate study medication . Use investigational drug within 28 day 5 halflives , whichever longer , precede first dose study medication ( ) . Blood donation excess 500 mL within 56 day prior dose intend donate within 30 day posttreatment followup visit . Presence suspect iron deficiency . Stool positive occult blood . Troponin I level 10 % coefficient variation assay . For female subject childbearing potential , positive serum pregnancy test . Female subject lactating . Positive urine drug screen ( UDS ) include alcohol . Positive HIV antibody , hepatitis C antibody hepatitis B surface antigen ( HBsAg ) . Positive urinary cotinine . Smoking history = 4 pack per day/year smoke 2 time within past 30 day prior screen . History drug abuse dependence within 6 month screen . History alcohol abuse within 6 month screen alcohol consumption past 6 month exceed 7 drinks/week woman 14 drinks/week men ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) . Presence active infection . Corrected QT interval ( QTc ) &gt; 450 msec . Pepsinogen level lower limit laboratory reference range ( LLRR ) . Active peptic ulcer disease ( PUD ) history PUD unknown etiology . Use prescription nonprescription drug ( ) , include oral contraceptive , herbal dietary supplement vitamin within 14 day , 5 halflives ( whichever longer ) prior first dose study medication . Consumption food drink contain grapefruit grapefruit juice , apple juice , Seville oranges , kumquat , pomelo , star fruit , red wine , charbroiled meat , cabbage vegetable mustard green family ( e.g. , kale , broccoli , watercress , collard green , kohlrabi , brussels sprout , mustard ) within 7 day prior first dose study medication ( ) . History cholecystectomy biliary tract disease . Any serious unstable preexist medical , psychiatric , condition could interfere subject 's safety , obtain informed consent compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>drug-drug interaction ,</keyword>
	<keyword>rosiglitazone ,</keyword>
	<keyword>safety</keyword>
	<keyword>CYP2C8 ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>CYP3A4 ,</keyword>
	<keyword>granisetron ,</keyword>
	<keyword>dolasetron ,</keyword>
	<keyword>CYP2D6 ,</keyword>
	<keyword>casopitant ,</keyword>
</DOC>